Kaskela Law LLC is investigating the fairness of the recently announced buyout of Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT) shareholders.

On March 9, 2025, Checkpoint announced that it had agreed to be acquired by Sun Pharmaceutical Industries Ltd. at an upfront price of $4.10 per share in cash plus a non-transferable contingent value right (CVR) worth up to an additional $0.70 in cash upon the achievement of certain milestones.  Following the closing of the proposed transaction, Checkpoint’s shareholders will be cashed out of their investment position and the company’s shares will no longer be publicly traded.

The investigation seeks to determine whether Checkpoint’s shareholders will be receiving sufficient monetary consideration for their shares, and whether the company’s officers and/or directors breached their fiduciary duties or violated the securities laws in agreeing to the buyout price.  Notably, at the time the proposed transaction was announced, several stock analysts were maintaining price targets for the company’s shares well above the buyout price at between $7.00 – $9.00 per share.

Checkpoint shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by completing the form on this page, to receive additional information about this investigation and their legal rights and options.

CONTACT:

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
([email protected])
Adrienne Bell, Esq.
([email protected])
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 229 – 0750